Streetbeat News

BIAF

bioAffinity Technologies, Inc.

https://www.bioaffinitytech.com

Industry

Medical - Diagnostics & Research

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Open

0.99

Mkt cap

14M

Volume

53K

High

0.99

P/E Ratio

-1.13

52-wk high

3.62

Low

0.91

Div yield

N/A

52-wk low

0.91

In Friday's pre-market session, several healthcare stocks experienced significant movements. Envoy Medical, Theriva Biologics, and Athira Pharma saw notable gains, while Lexicon Pharmaceuticals and others faced declines. Earnings reports influenced some stock movements.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 12:12 pm

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 12:11 pm

bioAffinity Technologies has secured a Japanese patent for its CyPath Lung, a stand-alone lung cancer detection assay. This adds to their existing portfolio of 17 U.S. and international patents in diagnostics and cancer therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:17 pm

Several healthcare stocks experienced significant price movements in Wednesday's after-market session. CNS Pharma, DBV Technologies, and Molina Healthcare were among the gainers, while Enveric Biosciences and Evotec saw declines. Molina Healthcare's rise is linked to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 8:31 pm

In Friday's after-market session, several healthcare stocks experienced significant movements. VSee Health (VSEE) saw a notable increase of 66.5%, while GRI Bio (GRI) rose by 21.58%. On the downside, SAB Biotherapeutics (SABS) fell by 7.8%, and Healthcare Triangle (HCTI) decreased by 7.21%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 8:31 pm

bioAffinity Technologies shares fell following the announcement of a $2.66 million direct offering of 2.05 million shares.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 5:51 pm

bioAffinity Technologies has announced a $2.66 million registered direct offering and a concurrent private placement. The offering includes 2.05 million shares priced at $1.30 each and warrants for 2.66 million shares at $1.50 per share, exercisable after stockholder approval for up to five years. The closing is expected around October 21, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 4:53 pm

bioAffinity's CyPath Lung Cancer Test has received support from new flow cytometry guidelines. VP Jennifer Rebeles contributed to an expert panel that published best practices for rare sample testing in a peer-reviewed journal.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:11 pm

bioAffinity Technologies has appointed J. Michael Edwards as its Chief Financial Officer. Edwards, who has been serving as interim CFO since September 15, has a long history with the company, including overseeing its IPO in 2022.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:09 pm

bioAffinity Technologies has secured a U.S. Federal Supply Schedule contract for its CyPath Lung test, a noninvasive diagnostic for early-stage lung cancer. This will provide U.S. Veterans and other federal health services patients with access to the test.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.